Interferon-induced prolonged biochemical response reduces hepatocarcinogenesis in hepatitis C virus infection

Journal of Medical Virology

Volumn 79, Issue 10, 2007, Pages 1485-1490

  Arase, Yasuji ^a   Ikeda, Kenji ^a   Suzuki, Fumitaka ^a   Suzuki, Yoshiyuki ^a   Kobayashi, Masahiro ^a   Akuta, Norio ^a   Hosaka, Tetsuya ^a   Sezaki, Hitomi ^a   Yatsuji, Hiromi ^a   Kawamura, Yusuke ^a   Kobayashi, Mariko ^a   Kumada, Hiromitsu ^a  

^a TORANOMON HOSPITAL   (Japan)

Author keywords

Biochemical response; Chronic hepatitis C; Hepatocellular carcinoma; Interferon

Indexed keywords

ALPHA FETOPROTEIN; ALPHA INTERFERON; ALPHA2A INTERFERON; AMINOTRANSFERASE; BETA INTERFERON; INTERFERON; RECOMBINANT ALPHA2A INTERFERON; RIBAVIRIN; VIRUS RNA;

ADULT; AGED; ARTICLE; BIOPSY; CHEMICAL ANALYSIS; CONTROLLED STUDY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HISTOLOGY; HUMAN; HUMAN TISSUE; LIVER CARCINOGENESIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE;

AGE FACTORS; ALPHA-FETOPROTEINS; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; BIOPSY; CARCINOMA, HEPATOCELLULAR; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON-ALPHA; INTERFERON-BETA; INTERFERONS; LIVER; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; TRANSAMINASES; TREATMENT OUTCOME;

HEPATITIS C VIRUS;

EID: 34548247217     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.20925     Document Type: Article

References (32)

1. Albadalejo J, Alonso R, Antinozzi R, Bogard M, Bourgault AM, Colucci G, Fenner T, Petersen H, Sala E, Vincelette J, Young C. 1998. Multicenter evaluation of the COBAS AMPLICOR HCV assay, an integrated PCR system for rapid detection of hepatitis C virus RNA in the diagnostic laboratory. J Clin Microbiol 36:862-865.
2. Arase Y, Ikeda K, Murashima N, Chayama K, Tsubota A, Koida I, Suzuki Y, Saitoh S, Kobayashi M, Kumada H. 1997. The long term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer 79:1494-1500.
3. Arase Y, Ikeda K, Chayama K, Murashima N, Tsubota A, Nakamura I, Suzuki Y, Saitoh S, Kobayashi M, Kobayashi M, Kobayashi M, Kumada H. 1999. Clinical and virological features of chronic hepatitis C carriers with normal alanine aminotransferase levels despite positive serum HCV-RNA after interferon therapy. J Gastroenterol 34:594-599.
4. Arase Y, Chayama K, Ikeda K, Tsubota A, Suzuki Y, Saitoh S, Kobayashi M, Suzuki F, Akuta N, Someya T, Kobayashi M, Kumada H. 2001. Randomized controlled clinical trial of lymphoblastoid interferon-alpha for chronic hepatitis C. Hepatol Res 21:55-66.
5. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Sheuer PJ. 1994. Classification of chronic hepatitis: Diagnosis, grading and staging. Hepatology 19:1513-1520.
6. Deutsch HF. 1991. Chemistry and biology of alpha-fetoprotein. Adv Cancer Res 56:253-312.
7. Doglio A, Laffont C, Caroli-Bosc FX, Rochet P, Lefebvre J. 1999. Second generation of the automated Cobas Amplicor HCV assay improves sensitivity of hepatitis C virus RNA detection and yields results that are more clinically relevant. J Clin Microbiol 37:1567-1569.
8. Dusheiko G, Schmilovitz-Weiss H, Brown D, McOmish F, Yap PL, Sherlock S, McIntyre N, Simmonds P. 1994. Hepatitis C virus genotypes: An investigation of type-specific differences in geographic origin and disease. Hepatology 19:13-18.
9. Fogler WE, Volker K, McCormick KL, Watanabe M, Ortaldo JR, Wiltrout RH. 1996. NK cell infiltration into lung, liver, and subcutaneous B16 melanoma is mediated by VCAM-1/VLA-4 interaction. J Immunol 56:4707-4714.
10. Gutterman JU. 1994. Cytokine therapeutics: Lessons from interferon alpha. Proc Natl Acad Sci 91:1198-1205.
11. Hagiwara H, Hayashi N, Mita E, Hiramatsu N, Ueda K, Takehara T, Yuki N, Kasahara A, Fusamoto H, Kamada T. 1992. Detection of hepatitis C virus RNA in chronic non-A, non-B liver disease. Gastroenterology 102:692-694.
12. Harrington DP, Fleming TR. 1983. A class of rank test procedures for censored survival data. Biomedica 62:553-566.
13. Ikeda K, Arase Y, Saitoh S, Kobayashi M, Suzuki Y, Suzuki F, Tsubota A, Chayama K, Murashima N, Kumada H. 2000. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 32:228-232.
14. Ikeda K, Saitoh S, Kobayashi M, Suzuki Y, Suzuki F, Tsubota A, Arase Y, Murashima N, Chayama K, Kumada H. 2001. Long-term interferon therapy for 1 year or longer reduces the hepatocellular carcinogenesis rate in patients with liver cirrhosis caused by hepatitis C virus: A pilot study. J Gastroenterol Hepatol 16:406-415.
15. Imai Y, Kawata S, Tamura S, Yabuuchi I, Noda S, Inada M, Maeda Y, Shirai Y, Fukuzaki T, Kaji I, Ishikawa H, Matsuda Y, Nishikawa M, Seki K, Matsuzawa Y, Osaka Hepatocellular Carcinoma Prevention Study Group. 1998. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Ann Intern Med 129:94-99.
16. Kasahara A, Hayashi N, Mochizuki K, Takayanagi M, Yoshioka K, Kakumu S, Iijima A, Urushihara A, Kiyosawa K, Okuda M, Hino K, Okita K, Osaka Liver Disease Study Group. 1998. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Hepatology 27:1394-1402.
17. Lester EP, Miller JB, Baron JM, Yachnin S. 1978. Inhibition of human lymphocyte transformation by human alpha-foetoprotein (HAFP): Studies on the mode of HAFP action and the role of HAFP polymorphism. Immunology 34:189-194.
18. Lindner DJ. 2002. Interferons as antiangiogenic agents. Curr Oncol Rep 4:510-514.
19. Lindsay KL, Trepo C, Heintges T, Shiffman ML, Gordon SC, Hoefs JC, Schiff ER, Goodman ZD, Laughlin M, Yao R, Albrecht JK, Hepatitis Interventional Therapy Group. 2001. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 34:395-403.
20. Lu CY, Changelian PS, Unanue ER. 1984. Alpha-fetoprotein inhibits macrophage expression of la antigen. J Immunol 132:1722-1727.
21. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. 2001. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 358:958-965.
22. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK, Hepatitis Interventional Therapy Group. 1998. Interferon alfa-2b alone or in combination witb ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 339:1485-1492.
23. McHutchison JG, Poynard T, Pianko S, Gordon SC, Reid AE, Dienstag J, Morgan T, Yao R, Albrecht J, The International Hepatitis Interventional Therapy Group. 2000. The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. Gastroenterology 119:1317-1323.
24. Murphy D, Detjen KM, Welzel M, Wiedenmann B, Rosewicz S. 2001. Interferon-alpha delays S-phase progression in human hepatocellular carcinoma cells via inhibition of specific cyclin-dependent kinases. Hepatology 33:346-356.
25. Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, Shiomi S, Seki S, Kobayashi K, Otani S. 1995. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 346:1051-1055.
26. Parmelee M, Evenson M, Deutsch H. 1978. The presence of fatty acids in human alpha-fetoprotein. J Biol Chem 253:2114-2119.
27. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J, International Hepatitis Interventional Therapy Group (IHIT). 1998. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 52:1426-1432.
28. Reichard O, Norkrans G, Fryden A, Braconier JH, Sonnerborg A, Weiland O, The Swedish Study Group. 1998. Randomised, double-blind, placebo-controlled trial of interferon alpha 2b with and without ribavirin for chronic hepatitis C. Lancet 351:83-87.
29. Scarpa S, Giuffrida A, Palumbo C, Vasaturo F, Signorelli P, Forni G, Modesti M, Ferrantini M, Belardelli F, Musiani P, Modesti A. 1997. Extracellular matrix remodelling in a murine mammary adenocarcinoma transfected with the interferon-alpha 1 gene. J Pathol 181:116-123.
30. Schalm SW, Hansen BE, Chemello L, Bellobuono A, Brouwer JT, Weiland O, Cavalletto L, Schvarcz R, Ideo G, Alberti A. 1997. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers. J Hepatol 26:961-966.
31. Wang W, Alpert E. 1995. Downregulation of phorbol 12-myristate 13-acetate-induced tumor necrosis factor-alpha and interleukin-1beta production and gene expression in human monocytic cells by human alpha-fetoprotein. Hepatology 22:921-928.
32. Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, O'Grady J, Reichen J, Diago M, Lin A, Hoffman J, Brunda MJ. 2000. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 343:1666-1672.